Preoperative positron emission tomography with fluorine-18- fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection

World Journal of Surgery

Volumn 30, Issue 9, 2006, Pages 1736-1741

  Hatano, Etsuro ^a   Ikai, Iwao ^a   Higashi, Tatsuya ^a   Teramukai, Satoshi ^b   Torizuka, Tatsuo ^c   Saga, Tsuneo ^a   Fujii, Hideaki ^a   Shimahara, Yasuyuki ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c HAMAMATSU MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; CANCER MORTALITY; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 33748757920     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-005-0791-5     Document Type: Conference Paper

References (23)

1. Imamura H, Matsuyama Y, Miyagawa Y, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999;86(8): 1032-1038.
2. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101(4): 796-802.
3. Shimada M, Hasegawa H, Gion T, et al. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology 1999;46(28): 2469-2475.
4. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001;39(5): 883-917.
5. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002;32(1): 35-46.
6. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62(6): 816-822.
7. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83(5): 918-924.
8. Lyshchik A, Higashi T, Nakamoto Y, et al. Dual-phase (18)F-fluoro-2- deoxy- d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2004;1515.
9. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36(10): 1811-1817.
10. Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64(14): 860-865.
11. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997;38(9): 1337-1344.
12. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35(12): 1965-1969.
13. Jeng LB, Changlai SP, Shen YY, et al. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology 2003;50(54): 2154-2156.
14. Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004;130(5): 266-272.
15. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94(11): 3314-3319.
16. Wudel LJ Jr, Delbeke D, Morris D, et al. The role of [18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69(2): 117-124; discussion 124-126.
17. Schroder O, Trojan J, Zeuzem S, et al. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 1998;37(8): 279-285.
18. Liangpunsakul S, Agarwal D, Horlander JC, et al. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation. Transplant Proc 2003;35(8): 2995-2997.
19. Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96(6): 1877-1880.
20. Kong YH, Han CJ, Lee SD, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma. Korean J Hepatol 2004;10(4): 279-287.
21. Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39(10): 961-968.
22. Del Gaudio M, Grazi GL, Principe A, et al. Influence of prognostic factors on the outcome of liver transplantation for hepatocellular carcinoma on cirrhosis: a univariate and multivariate analysis. Hepatogastroenterology 2004;51(56):510-514.
23. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001;136(1): 25-30.